Taro Pharmaceutical Industries is a multinational, science-based pharmaceutical company. Co. develops, manufactures and markets prescription and over-the-counter pharmaceutical products mainly in the U.S., Canada and Israel. Co.'s main focus includes semi-solids formulations, such as creams and ointments and other dosage forms such as liquids, capsules and tablets, in the dermatological and topical, cardiovascular, neuropsychiatric and anti-inflammatory therapeutic categories. Co. manufactures finished dosage form pharmaceutical products for sale in Israel and for export; and produces active pharmaceutical ingredients used in the manufacture of finished dosage form pharmaceutical products. The TARO stock yearly return is shown above.
The yearly return on the TARO stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the TARO annual return calculation with any dividends reinvested as applicable (on ex-dates).
|